AR075177A1 - Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros. - Google Patents
Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros.Info
- Publication number
- AR075177A1 AR075177A1 ARP100100186A ARP100100186A AR075177A1 AR 075177 A1 AR075177 A1 AR 075177A1 AR P100100186 A ARP100100186 A AR P100100186A AR P100100186 A ARP100100186 A AR P100100186A AR 075177 A1 AR075177 A1 AR 075177A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- atom
- cycloalkyl
- absent
- carbon
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyclohexyl carbon Chemical group 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Compuesto que responde a la formula (1) en la que U representa un átomo de oxígeno o un átomo de nitrogeno, sabiendo que cuando U representa un átomo de oxígeno, entonces R5 está ausente; n es igual a 0, 1, 2 o 3; p es igual a 0, 1 o 2; D representa un átomo de oxígeno, un grupo -NH- o un enlace; W representa un átomo de carbono o de nitrogeno; X representa un heteroátomo elegido entre un átomo de oxígeno o un átomo de azufre; R1, R2, R3 y R4 representan, independientemente entre sí, un átomo de hidrogeno, o un grupo alquilo C1-6 o bien, o (i) R1 y R2 pueden formar con el átomo de carbono al que están unidos un grupo cicloalquilo C3-10 y/o (ii) R3 y R4 pueden formar con el átomo de carbono al que están unidos un grupo cicloalquilo C3-10; Y representa un átomo de hidrogeno, un grupo alquilo C1-6, cicloalquilo C3-10, cicloalquil C3-10-oxilo, cicloalquil C3-10-alquil C1-6-oxilo, heterocicloalquilalquil C1-6-oxilo, un grupo -COOR1, arilo, arilalquilo, heteroarilo, heterocicloalquilo, ariloxilo, -C(O)-heterocicloalquilo, -C(O)arilo, -CH(OH)arilo, -NH-cicloalquilo estando eventualmente sustituidos dichos grupos con uno o varios sustituyentes elegidos entre un átomo de halogeno, un grupo hidroxilo, un grupo alquilo C1-6, alcoxilo C1-6, heterocicloalquilo o un grupo ariloxilo; R representa un átomo de hidrogeno o de halogeno; Z1 está ausente o representa un átomo de azufre, una funcion -NH-, -NHC(O)-, un grupo -S(O)-CH2-, -SCH2-, metileno o un grupo etileno; Z2 está ausente o representa un grupo metileno, un grupo =CH o =C(H)-; Z3 está ausente o representa un átono de oxígeno o un grupo metileno, un =CH o =C(H)-; sabiendo que Z2 solo representa un grupo =C(H)- cuando Z3 está presente y representa un grupo =C(H)-, y a la inversa, formando Z2 y Z3 así un enlace doble; sabiendo que Z2 y Z3, cuando están presentes, pueden estar comprendidos en un grupo cicloalquilo; Z4 es un átomo de hidrogeno, un átomo de carbono que forma eventualmente con un Z3 un grupo cicloalquilo C3-10 cuando Z3 es un grupo =CH, o está ausente, siendo entonces Z3 un grupo =C(H)- que forma un enlace doble con el carbono de ciclohexilo que está adyacente; R5 representa un átomo de hidrogeno o un grupo alquilo eventualmente sustituido con al menos un grupo hidroxilo, heterocicloalquilalquilo C1-6, amina o alquiloxilo, en forma de ácido, de base o de sal de adicion a un ácido o a una base.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0900359A FR2941457A1 (fr) | 2009-01-28 | 2009-01-28 | Derives de thiadiazoles et d'oxadiazoles leur preparation et leur application en therapeutique |
| FR0904137A FR2949464B1 (fr) | 2009-09-01 | 2009-09-01 | Derives de thiadiazoles et d'oxadiazoles, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075177A1 true AR075177A1 (es) | 2011-03-16 |
Family
ID=42261833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100186A AR075177A1 (es) | 2009-01-28 | 2010-01-27 | Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8546391B2 (es) |
| EP (1) | EP2391611B1 (es) |
| JP (1) | JP2012516312A (es) |
| KR (1) | KR20110112845A (es) |
| CN (1) | CN102365273A (es) |
| AR (1) | AR075177A1 (es) |
| AU (1) | AU2010209545A1 (es) |
| BR (1) | BRPI1007414A2 (es) |
| CA (1) | CA2750742A1 (es) |
| CL (1) | CL2011001839A1 (es) |
| CO (1) | CO6400221A2 (es) |
| CR (1) | CR20110403A (es) |
| DO (1) | DOP2011000245A (es) |
| EA (1) | EA201170983A1 (es) |
| EC (1) | ECSP11011224A (es) |
| IL (1) | IL214260A0 (es) |
| MA (1) | MA33069B1 (es) |
| MX (1) | MX2011007991A (es) |
| NI (1) | NI201100149A (es) |
| NZ (1) | NZ594244A (es) |
| PE (1) | PE20120362A1 (es) |
| TN (1) | TN2011000353A1 (es) |
| TW (1) | TW201031645A (es) |
| UY (1) | UY32405A (es) |
| WO (1) | WO2010086551A1 (es) |
| ZA (1) | ZA201105525B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2963005B1 (fr) * | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
| CN102557941B (zh) * | 2010-12-07 | 2015-04-22 | 成都睿智化学研究有限公司 | 一种螺环丙基甲酰衍生物的中间体化合物的制备方法 |
| WO2014054053A1 (en) * | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
| WO2014060381A1 (de) * | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| EP3071541B1 (en) * | 2013-11-21 | 2023-06-07 | Marquette University | Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform |
| WO2015106272A1 (en) * | 2014-01-13 | 2015-07-16 | Harki Daniel A | Small molecule inhibitors of apobec3g and apobec3b |
| EP3034500A1 (en) * | 2014-12-17 | 2016-06-22 | Genkyotex Sa | Amido thiazole derivatives as NADPH oxidase inhibitors |
| WO2016131192A1 (en) * | 2015-02-17 | 2016-08-25 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences | Compounds and methods for inducing browning of white adipose tissue |
| CN106278895B (zh) * | 2015-05-15 | 2021-07-09 | Dic株式会社 | 羧酸化合物、其制造方法、使用该化合物的液晶组合物 |
| WO2019193540A1 (en) * | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2023060573A1 (en) * | 2021-10-15 | 2023-04-20 | Beijing Danatlas Pharmaceutical Co., Ltd. | Novel thiadiazolyl derivatives of dna polymerase theta inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100077A (en) | 1998-10-01 | 2000-08-08 | The Trustees Of Columbia University In The City Of New York | Isolation of a gene encoding diacylglycerol acyltransferase |
| FR2840301B1 (fr) | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
| WO2004004665A2 (en) * | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| US20050143384A1 (en) * | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| US7507832B2 (en) * | 2003-12-22 | 2009-03-24 | Eli Lilly And Company | Triazole PPAR modulators |
| GB0427328D0 (en) * | 2004-12-14 | 2005-01-19 | Astrazeneca Ab | Chemical compounds |
| KR20080015113A (ko) | 2005-06-11 | 2008-02-18 | 아스트라제네카 아베 | Ｄｇａｔ 억제제로서의 옥사디아졸 유도체 |
| GB0511851D0 (en) * | 2005-06-11 | 2005-07-20 | Astrazeneca Ab | Chemical compounds |
| WO2007115935A1 (en) | 2006-04-07 | 2007-10-18 | High Point Pharmaceuticals, Llc | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS |
-
2010
- 2010-01-27 TW TW099102288A patent/TW201031645A/zh unknown
- 2010-01-27 KR KR1020117019841A patent/KR20110112845A/ko not_active Withdrawn
- 2010-01-27 BR BRPI1007414-7A patent/BRPI1007414A2/pt not_active IP Right Cessation
- 2010-01-27 PE PE2011001392A patent/PE20120362A1/es not_active Application Discontinuation
- 2010-01-27 EP EP10707597.0A patent/EP2391611B1/fr active Active
- 2010-01-27 MX MX2011007991A patent/MX2011007991A/es not_active Application Discontinuation
- 2010-01-27 US US13/145,665 patent/US8546391B2/en not_active Expired - Fee Related
- 2010-01-27 AR ARP100100186A patent/AR075177A1/es not_active Application Discontinuation
- 2010-01-27 EA EA201170983A patent/EA201170983A1/ru unknown
- 2010-01-27 WO PCT/FR2010/050124 patent/WO2010086551A1/fr not_active Ceased
- 2010-01-27 NZ NZ594244A patent/NZ594244A/xx not_active IP Right Cessation
- 2010-01-27 AU AU2010209545A patent/AU2010209545A1/en not_active Abandoned
- 2010-01-27 JP JP2011546921A patent/JP2012516312A/ja not_active Withdrawn
- 2010-01-27 CN CN2010800142290A patent/CN102365273A/zh active Pending
- 2010-01-27 MA MA34128A patent/MA33069B1/fr unknown
- 2010-01-27 CA CA2750742A patent/CA2750742A1/fr not_active Abandoned
- 2010-01-28 UY UY0001032405A patent/UY32405A/es not_active Application Discontinuation
-
2011
- 2011-07-15 TN TN2011000353A patent/TN2011000353A1/fr unknown
- 2011-07-24 IL IL214260A patent/IL214260A0/en unknown
- 2011-07-25 EC EC2011011224A patent/ECSP11011224A/es unknown
- 2011-07-26 CR CR20110403A patent/CR20110403A/es unknown
- 2011-07-27 NI NI201100149A patent/NI201100149A/es unknown
- 2011-07-27 ZA ZA2011/05525A patent/ZA201105525B/en unknown
- 2011-07-28 CL CL2011001839A patent/CL2011001839A1/es unknown
- 2011-07-28 CO CO11094698A patent/CO6400221A2/es not_active Application Discontinuation
- 2011-07-28 DO DO2011000245A patent/DOP2011000245A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY32405A (es) | 2010-08-31 |
| ZA201105525B (en) | 2012-12-27 |
| ECSP11011224A (es) | 2011-08-31 |
| KR20110112845A (ko) | 2011-10-13 |
| TW201031645A (en) | 2010-09-01 |
| MA33069B1 (fr) | 2012-02-01 |
| BRPI1007414A2 (pt) | 2018-03-06 |
| EA201170983A1 (ru) | 2012-03-30 |
| NI201100149A (es) | 2011-11-01 |
| US20120040984A1 (en) | 2012-02-16 |
| PE20120362A1 (es) | 2012-05-04 |
| DOP2011000245A (es) | 2011-09-15 |
| US8546391B2 (en) | 2013-10-01 |
| CO6400221A2 (es) | 2012-03-15 |
| EP2391611B1 (fr) | 2014-04-30 |
| IL214260A0 (en) | 2011-09-27 |
| CL2011001839A1 (es) | 2012-01-06 |
| NZ594244A (en) | 2013-07-26 |
| CR20110403A (es) | 2011-09-21 |
| EP2391611A1 (fr) | 2011-12-07 |
| TN2011000353A1 (fr) | 2013-03-27 |
| CA2750742A1 (fr) | 2010-08-05 |
| MX2011007991A (es) | 2011-11-18 |
| WO2010086551A1 (fr) | 2010-08-05 |
| CN102365273A (zh) | 2012-02-29 |
| AU2010209545A1 (en) | 2011-08-18 |
| JP2012516312A (ja) | 2012-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075177A1 (es) | Derivados de tiadiazoles y oxadiazoles, metodo de preparacion, intermediarios de sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad y diabetes, entre otros. | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| CO6400139A2 (es) | Derivados de ciclopenta[c]pirool-2-carboxilatos, su preparación y su aplicación en terapéutica | |
| CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
| MX344927B (es) | Composición farmacéutica que contiene derivado de quinolina. | |
| ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
| AR047817A1 (es) | Derivados de aril- y heteroarilpiperidincarboxilatos, su preparacion y su aplicacion en terapeutica | |
| AR073136A1 (es) | Compuestos de pirrol | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| ECSP077215A (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| BRPI1009212B8 (pt) | Composto de piperazina capaz de inibir a prostaglandina d sintase, seus usos e composição farmacêutica | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| EA201490722A1 (ru) | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ МЕТАБОТРОПНОГО РЕЦЕПТОРА ГЛУТАМАТА mGluR5 | |
| CO6460742A2 (es) | Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica | |
| PH12013501572A1 (en) | 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators | |
| ES2559854T3 (es) | Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica | |
| MY146939A (en) | Derivatives of 7-alkynyl-1,8-naphthyridones, preparation method thereof and use of same in therapeutics | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| MX2011007272A (es) | Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1. | |
| PH12013501856A1 (en) | Novel octahydrothienoquinoline derivative, pharmaceutical composition comprising derivative, and use of these | |
| AR088021A1 (es) | Derivados de oxadiazoles y de piridazinas, su preparacion y su aplicacion en terapeutica | |
| GB2479692B (en) | Coelenteramide analogs | |
| PE20090602A1 (es) | Nuevos compuestos | |
| TN2011000474A1 (en) | Pyrazole compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |